electroCore Inc. has appointed Elena Bonfiglioli to its Board of Directors. She succeeds Bonfiglioli’s retiring board member Peter Cuneo.

“We continue to strengthen our corporate governance, and adding an accomplished executive like Elena is an important next step,” electroCore CEO Dan Goldberger stated.

Bonfiglioli has been working in the health sector for more than two decades. She is currently Microsoft’s global business leader for Healthcare, Pharma Life Sciences, and the International clinical applications’ solutions, responsible for go-to-market, commercial, and partnerships, enabling artificial intelligence (AI) transformation initiatives in health providers, paywrs and life sciences’ organizations globally.

Since 2023, Bonfiglioli has been a member of the Drug Information Association (DIA) for Europe, Middle East & Africa Regional Advisory Council, and serves as a board member of several startups in Europe and the Middle East, and as advisor for biopharma organizations. Bonfiglioli was selected twice as one of the top 50 AI Innovators by Intelligent Health and was a founding member of the Holomedicine Association; and vice chair of the DIGITALEUROPE Executive Council for Healthcare since its creation in 2021.

Bonfiglioli was a champion for secondary use of data to enhance research and activate the power of data to save lives. She recently joined the Women Health Initiative board, a community powered by Kearney. She is active in the longevity field and champions the shift to health enhanced by data and AI.

“I am excited about electroCore’s ability to address chronic pain and other challenges with a drug-free solution that is accessible for so many people, empowering consumers and patients to take control of their health outcomes,” Bonfiglioli said. “I look forward to bringing my experience, both with global companies like Microsoft and with startups around the world, to drive growth and market expansion.”

electroCore Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. The company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. The company also commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.